Comparison of different methods to investigate postprandial lipaemia

Netherlands Journal of Medicine

Volumn 67, Issue 1, 2009, Pages 13-20

  van Oostrom, A J H H M ^a,b   Alipour, A ^c   Sijmonsma, T P ^b   Verseyden, C ^b   Dallinga Thie, G M ^d   Plokker, H W M ^a   Castro Cabezas, M ^c  

^a ST ANTONIUS HOSPITAL   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c SINT FRANCISCUS GASTHUIS   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Capillary triglycerides; Lipoproteins; Nosuvastatin; Postprandial hyperlipidaemia; Remnant like particle cholesterol

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPOPROTEIN; REMNANT LIKE PARTICLE CHOLESTEROL; ROSUVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALIMENTARY LIPEMIA; AMBULATORY MONITORING; AREA UNDER THE CURVE; ARTICLE; CAPILLARY BLOOD; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; ORAL FAT LOADING TEST; RISK ASSESSMENT; SELF EXAMINATION; TRIACYLGLYCEROL BLOOD LEVEL;

AREA UNDER CURVE; CORONARY ARTERY DISEASE; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; PYRIMIDINES; REGRESSION ANALYSIS; SULFONAMIDES; TRIGLYCERIDES;

EID: 58849122764     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.
2. Davignon J, Cohn JS. Triglycerides: a risk factor for coronary heart disease. Atherosclerosis. 1996;124(suppl):S57-64.
3. O'Meara NM, Lewis GF, Cabana VG, Iverius PH, Getz GS, Polonsky KS. Role of basal triglyceride and high density lipopratein in determination of postprandial lipid and lipoprotein responses. J Clin Endocrinol Metab. 1992;75:465-71.
4. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation. 1979;60:473-85.
5. Weintraub MS, Grosskopf I, Rassin T, et al. Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years. BMJ. 1996;312:936-9.
6. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis. 1994;106:83-97.
7. Karpe F. Effects of diet on postprandial lipaemia: a suggestion for methodological standardization. Nutr Metab Cardiovasc Dis. 1997;7:44-55.
8. Halkes CJ, van Dijk H, de Jaegere PP, et al. Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin. Arterioscler Thromb Vasc Biol. 2001;21:1526-30.
9. Twickler ThB, Dallinga-Thie GM, Chapman MJ, Cohn JS. Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep. 2005;7:140-7.
10. Castro Cabezas M, Halkes CJ, Meijssen S, van Oostrom AJ, Erkelens DW. Diurnal triglyceride profiles: a novel approach to study triglyceride changes. Atherosclerosis. 2001;155:219-28.
11. Van Wijk JP, Castro Cabezas M, Halkes CJ, Erkelens DW. Effects of different nutrient intakes on daytime triacylglycerolemia in healthy, normolipemic, free-living men. Am J Clin Nutr. 2001;74:171-8.
12. Van Wijk JPH, Halkes CJM, Jaegere PPT, Plokker HWM, Erkelens DW, Castro Cabezas M. Normalization of daytime triglyceridemia by simvastatin in fasting normotriglyceridemic patients with premature coronary sclerosis. Atherosclerosis. 2003;171:109-16.
13. Van Oostrom AJ, van Dijk H, Verseyden C, et al. Addition of glucose to an oral fat load reduces pastprandial free fatty acids and prevents the postprandial increase in complement component 3. Am J Clin Nutr. 2004;79:510-5.
14. Van Wijk JP, van Oostrom AJ, Castro Cabezas M. Normal ranges of non-fasting triglycerides in healthy Dutch males and females. Clin Chim Acta. 2003;337:49-57.
15. Breedveld J, Hammink J, van Oosten HM. The Dutch food composition table, The Hague 1998. The Hague: Netherlands Center for Nutrition Education, 2002.
16. Netherlands Center for Nutrition Education. The Dutch national food consumption survey 1997-1998. The Hague: Netherlands Center for Nutrition Education, 2002.
17. Ossewaarde ME, Dallinga-Thie GM, Bots ML, et al. Treatment with hormone replacement therapy lowers remnant lipoprotein particles in healthy postmenopausal women: results from a randomized trial. Eur J Clin Invest. 2003;33:376-82.
18. Verseyden C, Meijssen S, Castro Cabezas M. Postprandial changes of apoB-100 and apoB-48 in TG rich lipoproteins in familial combined hyperlipidemia. J Lipid Res. 2002;43:274-80.
19. Dallinga-Thie GM, Linde-Sibenius TM, Kock LA, de Bruin TW. Apolipoprotein E2/E3/E4 genotyping with agarose gels. Clin Chem. 1995;41:73-5.
20. Van Oostrom AJ, Plokker HW, van Asbeck BS, et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis. 2006;185:331-9.
21. Delawi D, Meijssen S, Castro Cabezas M. Intra-individual variations of fasting plasma lipids, apolipoproteins and postprandial lipemia in familial combined hyperlipidemia compared to controls. Clin Chim Acta. 2003;328:139-45.
22. Van Oostrom AJ, Castro Cabezas M, Ribalta J, et al. Diurnal triglyceride profiles in healthy normolipidemic male subjects are associated to insulin sensitivity, body composition and diet. Eur J Clin Invest. 2000;30:964-71.
23. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-421.
24. Olsson AG, Pears J, McKellar J, Mizan J, Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol. 2001;88:504-8.
25. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92:152-60.
26. Guerin M, Egger P, Le Goff W, Soudant C, Dupuis R, Chapman MJ. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia. J Clin Endocrinol Metab. 2002;87:4991-5000.
27. Dane-Stewart CA, Watts GF, Pal S, et al. Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 2003;52:1279-86.
28. Lamendola C, Abbasi F, Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol. 2005;95:189-93.
29. Schaefer EJ, McNamara JR, Tayler T, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol. 2004;93:31-9.
30. Fontbonne A, Eschwege E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989;32:300-4.
31. Laakso M, Lehto S, Penttila I, Pyorala K. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation. 1993;88:1421-30.